The corporate venturing units of three healthcare companies have joined a consortium investing in the $45m series A round of Effector Therapeutics, a US-based biopharmaceutical company named after the eponymous molecule that selectively binds to a protein and regulates its biological activity. Novartis Venture Funds, GlaxoSmithKline’s SR One and Astellas Venture Management joined with venture capital (VC)…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.